Important limitations
- Individual claims and source links have not yet completed editorial verification.
- Evidence level, applicable study model, formulation, route and population remain unassigned.
Adipotide
Adipotide, also written FTPP or prohibitin-TP01, is a two-part synthetic peptide designed at the University of Texas MD Anderson Cancer Center.
Dosing & scaling, explained
The moderated mass amounts below are retained for comparison. Near-duplicates, mix-dependent volumes and device markings are excluded. This is educational source context, not a protocol or recommendation.
Mass amounts available for comparison
- Lower range455 mcg100-150 lb body weight
Recorded example with no verified study backing; shown for amount literacy only.
- Low-mid range680 mcg100-150 lb body weight
Recorded example with no verified study backing; shown for amount literacy only.
- Mid range910 mcg201-250 lb body weight
Recorded example with no verified study backing; shown for amount literacy only.
Only mcg or mg amounts are retained. The calculator derives mL, syringe units or pen clicks from the current vial strength, water volume and device.
No independently verified schedule
Evidence context
No clinical amount or schedule is inferred from this material. Source verification is pending, and every displayed amount remains educational context rather than guidance.
Storage, handling and interpretation
Product identity
Verify the exact compound, formulation and amount against the product label or certificate before calculation.
Storage & handling
Follow the product label, certificate and validated laboratory SOP; no universal storage assumption is applied here.
Prepared solutions
Label concentration and preparation date, use sterile technique where applicable, and follow a validated stability protocol.
Reported protocols for Adipotide
What published studies and recent community write-ups report about amounts, timing and course length. 1 clinical, 3 preclinical and 4 community-reported rows, each linked to its source. These are descriptions of what others report, not instructions, and nothing here is medical advice.
| Context | Dose | Frequency | Route | Course | Source |
|---|---|---|---|---|---|
| Clinical1 row | |||||
| First-in-human phase 1 trial (terminated, no results posted)Men with obesity and metastatic prostate cancer with no standard treatment options; 4 of a planned 39 enrolled | 0.03 mg/kg starting dose, with up to five escalating dose levels planned | Once daily | Subcutaneous | One 28-day cycleNone described; follow-up visits at 7 and 30 days after the last dose and phone contact every 3 months for a year | ClinicalTrials.gov2012 |
| MD Anderson registered this dose-escalation study in 2010 and began dosing in 2012, planning three participants per dose level with pharmacokinetic sampling on days 1 and 22. It was terminated at the principal investigator's request after four participants and no safety, pharmacokinetic or efficacy results were ever posted, so no human dose has been established. | |||||
| Preclinical3 rows | |||||
| Primate dose-finding escalation4 spontaneously obese female rhesus macaques aged 9 to 13 with a BMI of 34 to 45 | 0.10, 0.25, 0.43 and 0.75 mg/kg | Once daily, with the dose stepped up during the study | Subcutaneous | Escalation phase followed by a 2-week recovery period2-week recovery after dosing stopped, during which weight and waist measurements began to reverse | Science Translational Medicine (PubMed Central)2011 |
| Body weight, BMI and abdominal circumference fell in a time- and dose-dependent way while saline controls did not change. Serum creatinine rose slightly to moderately above 0.25 mg/kg without a matching rise in blood urea nitrogen, and the escalation set 0.43 mg/kg as the dose used in the later fixed-dose study. | |||||
| Primate fixed-dose efficacy study15 obese rhesus macaques with a BMI of 30 to 52 (10 treated, 5 given saline) | 0.43 mg/kg | Once daily | Subcutaneous, rotating between four sites on the trunk | 28 consecutive days4-week recovery period with weekly blood work, urinalysis and imaging | Science Translational Medicine (PubMed Central)2011 |
| Treated monkeys lost 7.4% to 14.7% of their starting body weight (about 10.6% on average) against a range of plus 1.0% to minus 3.5% in controls, and DEXA scans showed total body fat down 38.7% versus 14.8% in controls. The insulinogenic index improved by 48.5%, food intake fell, and lean monkeys given the same dose did not lose weight. | |||||
| Formal toxicology study in lean monkeys20 lean rhesus macaques in four groups of five (saline, low, middle and high dose) | 0.25, 0.43 or 0.75 mg/kg | Once daily | Subcutaneous | 28 consecutive daysThree animals per group were examined 24 hours after the last dose and two after a 4-week recovery | Science Translational Medicine (PubMed Central)2011 |
| This Good Laboratory Practice study recorded increased urine output, mild dehydration at the top dose, lower serum phosphorus and potassium, glucosuria, mild to moderate proteinuria and more renal epithelial cells in urine. The authors describe the findings as altered proximal tubular function and tubular injury that resolved during recovery. | |||||
| Community-reported4 rows | |||||
| Community ramp published by a peptide reference site | 250 mcg, then 500 mcg, then 750 mcg, then 1,000 mcg | Once daily, stepping up every 2 weeks | Subcutaneous | 4 to 8 weeks at mostNot specified beyond the cycle cap | Community resource2026 |
| This site publishes a four-step ramp with reconstitution math for a 10 mg vial in 3 mL, while labelling the compound caution-level and noting that development stopped over kidney toxicity. The figures are flat doses rather than the per-kilogram doses used in the animal work and have no trial behind them. | |||||
| Community band quoted by a 2026 guide | 250-500 mcg/kg per day, as the figure the guide says circulates | Once daily | Subcutaneous | 28 daysNone described; the guide says the program was shelved and advises against use | Community resource2026 |
| The author reports the number he sees used while stating plainly that no validated human dose exists and that anyone administering it is outside any tested safety framework. He recommends baseline and serial creatinine, BUN, eGFR and urinalysis for anyone who proceeds, and his page contains some descriptive errors about the original papers. | |||||
| Published-protocol table from a compound database | 0.43 mg/kg (primate optimum), 0.10-0.75 mg/kg (dose-finding), 0.03 mg/kg (trial start) | Once daily in every published protocol | Subcutaneous | 28 days4-week recovery in the primate work | Community resource2026 |
| This database reproduces only the doses that appear in published research and states explicitly that they are not a dosing recommendation and that no human efficacy data exist. It also points out that the longest published exposure is 28 days with a 4-week recovery, so nothing is known about repeated cycles. | |||||
| Evidence review of the human record | 0.03 mg/kg daily starting dose, the only human figure on record | Once daily | Subcutaneous | One planned 28-day cycleNot applicable | Community resource2026 |
| A 2026 evidence review concludes that the human record is not interpretable: four participants enrolled, the study closed and no tolerability, pharmacokinetic or escalation results were posted. It treats the primate proximal-tubule injury as the central translational problem and notes that long-term reversibility was never established. | |||||
How a course is commonly described
- Weeks 1-2Community-reported
Community pages describe a low flat starting dose, around 250 mcg daily, with abdominal measurements as the first thing to change. In the primate dose-finding work the first creatinine rises appeared once the dose passed 0.25 mg/kg, which is the point the animal data flag rather than any body measurement.
- Weeks 2-4Preclinical
The 28-day block is the only duration any published protocol used, in mice, in three primate species and in the terminated human trial. In the fixed-dose monkey study weight, BMI and abdominal circumference fell steadily across these four weeks while food intake also dropped.
- Recovery, 4 weeksPreclinical
Every primate study paired 28 days of dosing with a 4-week recovery period. Creatinine and the urinary findings returned toward baseline during it, and weight, BMI and abdominal circumference started to reverse, which is the clearest sign that the effect depends on continued dosing.
- Repeat cyclesCommunity-reported
No source describes a tested repeat cycle. Community pages cap use at 4 to 8 weeks and one database notes that nothing is known about the effect of repeated rounds of adipose vascular ablation on kidney reserve, because the published exposure stops at one 28-day block.
- No validated human dose, schedule or cycle length exists for adipotide. The flat milligram and microgram figures on community pages are not the per-kilogram doses the animal studies used, and the only registered human trial closed after four participants without posting results.
- Kidney proximal tubule injury was the dose-limiting finding in every primate study, appearing above 0.25 mg/kg and resolving in the 4-week recovery periods. Prohibitin is also present in kidney tubule cells, which is the usual explanation offered for this off-target effect.
- Published exposure stops at 28 days of daily dosing. The primate data also show that weight and waist measurements start to reverse once dosing stops, so nothing in the record supports a short course as a lasting change.
Sources for this section (7)
- Reversal of obesity by targeted ablation of adipose tissue
- A Peptidomimetic Targeting White Fat Causes Weight Loss and Improved Insulin Resistance in Obese Monkeys
- A First-in-Man, Phase I Evaluation of a Single Cycle of Prohibitin Targeting Peptide 1 in Patients With Metastatic Prostate Cancer and Obesity (NCT01262664)
Plus 4 community resources (dosing guides, forum threads and vendor write-ups), reported above but not linked.
Overview
Adipotide, also written FTPP or prohibitin-TP01, is a two-part synthetic peptide designed at the University of Texas MD Anderson Cancer Center. A cyclic nine-residue homing sequence binds prohibitin on the lining of the blood vessels that supply white fat, and a D-amino-acid proapoptotic sequence then disrupts the mitochondria of those cells, so the fat depot loses its blood supply and is reabsorbed. The approach reversed diet-induced obesity in mice in 2004 and produced about 11% weight loss in obese rhesus macaques in 2011, alongside dose-dependent and reversible changes in kidney proximal tubule function. The only human trial, a phase 1 study in men with obesity and metastatic prostate cancer, was terminated after four participants without posting results; adipotide has no approval anywhere and is sold only as a research chemical.
What researchers are exploring
These themes organize the educational information currently available. Individual claims remain under source review and are not treatment claims.
- 1
Research on Adipotide
Scientific studies and clinical trials on Adipotide's effects
- 2
Insulin Requirements Change (Area Under the Curve)
Analysis of insulin requirements changes in treated vs control groups
- 3
Adipotide Summary
Overview of Adipotide including dosing and cycling information
What is known and what still needs verification
Available context is organized without assigning unsupported study models or evidence grades.
- Not graded
Research on Adipotide
Scientific studies and clinical trials on Adipotide's effects
- Not graded
Insulin Requirements Change (Area Under the Curve)
Analysis of insulin requirements changes in treated vs control groups
Amounts recorded for Adipotide
These amount records are independent from vial strength, reconstitution volume and measuring device. A recorded source is not the same as study backing, and these values are not recommendations.
- 1100-150 lb body weight · lower endpointSign in for schedule, duration and source context.455 mcg
- 2100-150 lb body weight · upper endpointSign in for schedule, duration and source context.680 mcg
- 3201-250 lb body weight · lower endpointSign in for schedule, duration and source context.910 mcg
Chemistry identifiers
Sequence, synonyms and registry identifiers as recorded in PubChem, the National Library of Medicine's open chemistry database. Formula, mass and CAS number are summarized at the top of the page.
Sequence
Cys-Lys-Gly-Gly-Arg-Ala-Lys-Asp-Cys (cyclized through a disulfide bond), then a Gly-Gly linker, then two repeats of D-Lys-D-Leu-D-Ala-D-Lys-D-Leu-D-Ala-D-Lys
Also listed as
Adipotide, FTPP (fat-targeted proapoptotic peptide), Prohibitin-TP01, CKGGRAKDC-GG-D(KLAKLAK)2, HKPao, EX-A6186
InChIKey
GZESIPHLGJDZRG-VCWDIOOSSA-N
IUPAC name
(2R)-6-amino-2-[[(2R)-2-[[(2R)-2-[[(2R)-6-amino-2-[[(2R)-2-[[(2R)-2-[[(2R)-6-amino-2-[[(2R)-6-amino-2-[[(2R)-2-[[(2R)-2-[[(2R)-6-amino-2-[[(2R)-2-[[(2R)-2-[[(2R)-6-amino-2-[[2-[[2-[[(2R)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[2-[[2-[[(2S)-6-amino-2-[[(2R)-2-amino-3-sulfanylpropanoyl]amino]hexanoyl]amino]acetyl]amino]acetyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]amino]hexanoyl]amino]-3-carboxypropanoyl]amino]-3-sulfanylpropanoyl]amino]acetyl]amino]acetyl]amino]hexanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]hexanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]hexanoyl]amino]hexanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]hexanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]hexanoic acid
Limitations and unknowns
Sources
1 link carried over from the earlier page, awaiting verification.